U.S. orders 2.5 million more doses of Bavarian Nordic's vaccine for monkeypox
Reuters
Published Jul 01, 2022 10:38AM ET
Updated Jul 01, 2022 11:05AM ET
(Reuters) -The U.S. government has ordered 2.5 million more doses of Bavarian Nordic's vaccine for use against monkeypox outbreaks, the Department of Health and Human Services said on Friday.
The shot has already been cleared for both smallpox and monkeypox in the United States, where it is called Jynneos.
The U.S. government is ramping up its efforts to fight monkeypox by sending hundreds of thousands of vaccine doses to states in the coming months, expanding access for those most at risk and increasing supply to areas with high case numbers.
Globally, there have been more than 3,400 cases of monkeypox and one death since the outbreak began in May, according to a World Health Organization tally.
Bavarian Nordic said the total U.S. inventory of the vaccine would reach about 4.4 million doses when combined with a 2020 order for 1.4 million doses.
"This order of additional Jynneos vaccine will help us push out more vaccine quickly, knowing that we have more doses on the way in the coming months," HHS Secretary Xavier Becerra said.
Deliveries under the latest contract will start in the fourth quarter of 2022 and continue through early 2023, the company said.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.